Key result
This letter discusses the limitations of existing studies on anti-inflammatory interventions for atrial fibrillation prevention, emphasizing the need for well-powered randomized trials.
No takes yet. Share an insight, caveat, or question.
This reply emphasizes the need for well-powered randomized trials to determine if modifying inflammation can reduce the clinical burden of atrial fibrillation.
C. J. Boos (2005) conducted a letter in Atrial fibrillation. This letter discusses the limitations of existing studies on anti-inflammatory interventions for atrial fibrillation prevention, emphasizing the need for well-powered randomized trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: